Matrix OI provides the surgeon, hospital and patient with a verified osteoinductive construct after sterilization. It includes Stem Cell Containment technology which allows for up to 60 percent absorption of the graft’s volume.
“We are excited about our strategic partnership with CellRight Technologies,” said Keith Peeples, president and CEO of BME. “As a corporate partner, CellRight offers BME the expertise in orthobiologics that will position both companies for innovative product development and aggressive market penetration. Matrix OI is a whole new category of allograft tissue by confirming osteoinductivity after sterilization. Its design characteristics behave like a shape memory implant, which fits nicely into our product portfolio.”
BME is designs and develops Nitinol shape memory bone fixation systems.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
